We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
These reports outline the MHRA’s Corporate and Business Plans, detailing the agency's strategic direction over the next three years.
Introduction The Medicines and Healthcare products Regulatory Agency…
Information on Medicines and Healthcare products Regulatory Agency spending over £25,000.
MHRA transactions over £500 made using the government procurement card (GPC).
Performance data for MHRA key performance indicators (KPIs) and information on the expected timeline to complete a specific regulatory function.
Information on how the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG) is controlling spend on branded medicines in the NHS.
A programme to help decision making across the lifecycle of products, benefitting both regulatory and health technology assessment (HTA) evaluations.
This report examines three innovative projects funded through the Veterans’ Health Innovation Fund competition
MHRA performance metrics for clinical trials and established medicines assessment.
Progress made in delivering the Patient Involvement Strategy, October 2021 - January 2025.
Minutes of a meeting held between the government, NHS England and ABPI about the 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG).
Information on how the 2019 voluntary scheme for branded medicines pricing and access (VPAS) controlled spend on branded medicines in the NHS between 2019 and 2023.
Meeting minutes taken from meetings of the Vaccine Benefit Risk Expert Working Group (VBREWG) held between 20 September 2022 and 5 May 2023.
Meeting minutes taken from meetings of the Vaccine Benefit Risk Expert Working Group (VBREWG) held between 1 June 2021 and 19 November 2021.
Meeting minutes taken from meetings of the Vaccine Benefit Risk Expert Working Group (VBREWG) held between 3 December 2021 and 29 March 2022.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).